Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study.
acute lymphoblastic leukemia
blinatumomab
minimal residual disease
pediatric
real world
survival
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
19
12
2021
received:
11
08
2021
accepted:
20
12
2021
pubmed:
20
1
2022
medline:
6
5
2022
entrez:
19
1
2022
Statut:
ppublish
Résumé
Prior to regulatory approval of blinatumomab in pediatric patients with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (R/R Ph- BCP-ALL), blinatumomab was made available via an expanded access program (EAP). This retrospective observational study included patients receiving blinatumomab in the EAP between January 1, 2014 and June 30, 2017 who were followed until death, entry into a clinical trial, end of follow-up, or end of the study period (December 31, 2017), whichever occurred first. Among 113 children enrolled, 72 were diagnosed with R/R Ph- BCP-ALL and 41 were minimal residual disease positive (MRD+, either Ph- or Ph+). In the R/R group, 38 (53%) patients achieved hematological response within two cycles. Of these, 19 (50%) proceeded to hematopoietic stem cell transplantation (HSCT) without bridging myelosuppressive therapy. Of 36 patients in the R/R group evaluable for MRD, 30 (83%) had an MRD response. In the R/R group, median relapse-free survival was 5.4 months and median overall survival (OS) was 8.2 months. Of 36 patients in the MRD+ group who were evaluable for MRD after two cycles, 27 (75%) had an MRD response. Overall, 24 (59%) of the MRD+ patients proceeded to HSCT without other bridging therapy. Median disease-free survival was 13.6 months; median OS was not reached. In this real-world pediatric cohort, blinatumomab was effective within two cycles. Over half of patients with R/R Ph- BCP-ALL achieved hematological response and most achieved MRD response in the MRD+ group, confirming the efficacy of blinatumomab in pediatric trials.
Sections du résumé
BACKGROUND
Prior to regulatory approval of blinatumomab in pediatric patients with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (R/R Ph- BCP-ALL), blinatumomab was made available via an expanded access program (EAP).
PROCEDURE
This retrospective observational study included patients receiving blinatumomab in the EAP between January 1, 2014 and June 30, 2017 who were followed until death, entry into a clinical trial, end of follow-up, or end of the study period (December 31, 2017), whichever occurred first.
RESULTS
Among 113 children enrolled, 72 were diagnosed with R/R Ph- BCP-ALL and 41 were minimal residual disease positive (MRD+, either Ph- or Ph+). In the R/R group, 38 (53%) patients achieved hematological response within two cycles. Of these, 19 (50%) proceeded to hematopoietic stem cell transplantation (HSCT) without bridging myelosuppressive therapy. Of 36 patients in the R/R group evaluable for MRD, 30 (83%) had an MRD response. In the R/R group, median relapse-free survival was 5.4 months and median overall survival (OS) was 8.2 months. Of 36 patients in the MRD+ group who were evaluable for MRD after two cycles, 27 (75%) had an MRD response. Overall, 24 (59%) of the MRD+ patients proceeded to HSCT without other bridging therapy. Median disease-free survival was 13.6 months; median OS was not reached.
CONCLUSIONS
In this real-world pediatric cohort, blinatumomab was effective within two cycles. Over half of patients with R/R Ph- BCP-ALL achieved hematological response and most achieved MRD response in the MRD+ group, confirming the efficacy of blinatumomab in pediatric trials.
Substances chimiques
Antibodies, Bispecific
0
blinatumomab
4FR53SIF3A
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29562Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62(1):61-73.
Ma H, Sun H, Sun X. Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis. Sci Rep. 2014;4:4227.
Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541-1552.
Locatelli F, Whitlock JA, Peters C, et al. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia. 2020;34(9):2473-2478. https://doi.org/10.1038/s41375-020-0770-8
Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120(14):2807-2816.
Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 2013;14(6):e205-e217.
Pierro J, Hogan LE, Bhatla T, Carroll WL. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2017;17(8):725-736.
Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531. https://doi.org/10.1182/blood-2017-08-798322
van Dongen JJ, van der Velden VH, Bruggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996-4009. https://doi.org/10.1182/blood-2015-03-580027
Gokbuget N, Dombret H, Giebel S, et al. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology. 2019;24(1):337-348.
Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood. 2015;126(8):964-971. https://doi.org/10.1182/blood-2015-03-633685
von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381-4389.
Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):843-854.
Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):833-842.
European Medicines Agency. BLINCYTO summary of product characteristics. European Medicines Agency. Accessed November 20, 2021. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf
European Medicines Agency. BLINCYTO: European public assessment report procedural steps. European Medicines Agency; 2021. Accessed November 20, 2021. https://www.ema.europa.eu/en/documents/procedural-steps-after/blincyto-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
Locatelli F, Zugmaier G, Mergen N, et al. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020;10(7):77.
NIH. Observational study of blinatumomab. NIH. Accessed November 17, 2021. https://clinicaltrials.gov/ct2/show/NCT03117621?term=NCT03117621&draw=2&rank=1
Locatelli F, Zugmaier G, Mergen N, et al. Blinatumomab in children with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R-ALL): final results of 110 patients treated in an expanded access study (RIALTO). Blood. 2020;136(Supplement 1):24-25.
Locatelli F, Zugmaier G, Bader P, et al. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor and molecularly resistant acute lymphoblastic leukemia (R/R ALL): updated analysis of 110 patients treated in an expanded access study (RIALTO). Blood. 2019;134(Supplement_1):1294.